EMREmerson Electric
Q4 2026
EPS
$1.86
est $1.85+0.4%
Revenue
$5.20B
est $5.12B+1.6%

Underlying orders rose 14% on long-cycle project work, and management is backing it with fiscal 2027 adjusted EPS guidance of about $7.25. Automation demand is still expanding.

Quarterly EPS — reported vs estimate
Stock picks

CVS Is Reportedly Breaking Itself in Two

Reports say CVS Health is weighing a split that would unwind its landmark Aetna merger, but the structure, timeline, and who absorbs billions in debt remain unanswered questions heading into a critical earnings call.

Fiscal 2026 was a pivotal year for Cencora, as we expanded our MSO platform through the acquisition of OneOncology, sharpened the focus of our portfolio and delivered record results.

Mauch is framing the $65 billion distributor as an oncology services owner, with OneOncology anchoring the MSO platform on the fiscal 2026 earnings call. The payoff investors should track is whether those practice economics keep lifting margins in fiscal 2027.

Sponsored

CORCencora
Q4 2026
EPS
$4.66
est $4.57+1.9%
Revenue
$88.35B
est $87.91B+0.5%

Cencora guided fiscal 2027 adjusted EPS to $19.40 to $19.75, implying 8% to 10% growth, after a fifth straight quarterly beat. OneOncology did the heavy lifting, and the dividend was raised to $0.66 a share.

Quarterly EPS — reported vs estimate
UTHRUnited Therapeutics
Q3 2026
EPS
$5.71
est $6.04-5.5%
Revenue
$833M
est $781M+6.6%

Record quarterly revenue came in well ahead of estimates on 13% growth in Tyvaso DPI, yet earnings missed because a $130 million nondeductible charge for the Thymmune acquisition pushed the tax rate to 31% from 23%. The miss traces to that pipeline bill rather than demand, and management just authorized another $2.0 billion buyback.

Quarterly EPS — reported vs estimate
CVSCVS Health
Q3 2026
EPS
$2.09
est $1.65+26.6%
Revenue
$108.40B
est $104.69B+3.5%

Aetna is the story: the medical benefit ratio improved to 91.3% from 92.8%, a managed-care cost trend moving the right way. Management raised full-year adjusted EPS guidance to at least $8.20 from $7.90 to $8.10.

Quarterly EPS — reported vs estimate
ZBHZimmer Biomet
Q3 2026
EPS
$1.90
est $1.88+1.0%
Revenue
$2.06B
est $2.04B+1.1%

Knees, still Zimmer Biomet's biggest franchise, shrank 2.6% in constant currency, and the quarter beat anyway because hips, sports medicine and technology all grew at upper single to double-digit rates. Management raised the low end of full-year revenue growth to 4.4% and narrowed adjusted EPS guidance to $8.50 to $8.60. Diversification is carrying the company now.

Quarterly EPS — reported vs estimate
CRCLCircle Internet Group
Q3 2026
EPS
$0.84
est $0.38+121.8%
Revenue
$865M
est $789M+9.7%

The earnings beat is real but borrowed: $182 million of one-time ARC token presale revenue drove it, while core reserve income fell 8%. Management left full-year guidance untouched. Keep an eye on the stock through the call.

Quarterly EPS — reported vs estimate

Sponsored